Integra prices $450M in senior secured notes to refinance debt
What's the deal? Integra LifeSciences has priced $450 million in 9.500% senior secured notes due 2033. The medical technology company, listed on the Nasdaq as IART, expects the sale to close on or about October 19, 2026, subject to customary conditions.
What's the endgame? Integra intends to use the net proceeds, along with borrowings under new credit facilities, to refinance its existing credit facilities and cover related fees. The notes are part of a broader refinancing transaction.
The details: The notes will be general senior secured obligations, guaranteed by Integra's wholly-owned domestic subsidiaries that already back its senior secured credit facilities. They were offered only to qualified institutional buyers and certain non-US persons, and have not been registered under the Securities Act.
What does Integra do? The Princeton, N.J.-based company builds technologies for neurosurgery and tissue reconstruction, two fields that it says "demand exceptional expertise and precision."
The signal: At $450 million, the raise sits in the upper tier of debt deals in the sector — a sizeable move that lets Integra reset its capital structure rather than fund new expansion. For a mature medtech player, refinancing on fresh terms is a bet on stability over speed.
Read more: AP News
Image credit: Generated with Gemini
